Swedish Summer is over and, at Xintela, we are preparing for an exciting Autumn. Since our listing in the Spring, the company has developed in a very positive way and we are on track with the milestones we have set.
The purpose of our newsletter is to provide a better understanding of Xintela’s operations, to update readers on the company’s development and to comment on the status of our projects. In this newsletter, we will provide an update on XACT (Xintela Assay for Cell Therapy), which is Xintela’s quality test for cartilage cells and stem cells. In addition to giving a better insight into how XACT works, we will provide information on how we have further strengthened the project through the acquisition late last year of antibodies for another marker, integrin α11β1.
It is also noteworthy that a report from Global Data predicts that the sales of drugs for the treatment of glioblastoma will increase significantly in the next eight years. Treatments today are insufficient and there is great interest in identifying new methods and new target molecules for the treatment of glioblastoma. In our newsletter you can read an interview in BioStock where I responded to questions regarding our glioblastoma project.
Kind regards,
Evy Lundgren-Åkerlund
CEO Xintela AB
